Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders

X
Trial Profile

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Ciclosporin (Primary) ; Clofarabine (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Acute myeloid leukaemia; Adrenoleucodystrophy; Alpha-Mannosidosis; B-cell lymphoma; Bone marrow disorders; Diffuse large B cell lymphoma; Follicular lymphoma; Globoid cell leukodystrophy; Haematological malignancies; Haemoglobinopathies; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Metabolic disorders; Metachromatic leukodystrophy; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VII; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Osteopetrosis; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2023 Planned End Date changed from 20 Dec 2023 to 20 Dec 2025.
    • 07 Dec 2023 Planned primary completion date changed from 20 Dec 2023 to 20 Dec 2025.
    • 31 Mar 2021 Planned End Date changed from 20 Dec 2022 to 20 Dec 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top